New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease
Longer-term survival results underscoring role of KEYTRUDA (pembrolizumab) in multiple cancer types, including advanced nonsquamous non-small cell lung cancer (KEYNOTE-189)
The drive also conducted a mega health camp, cancer screening for women and men, ENT screening for children, and blood donation drive
Lutio has the potential to offer significant cost savings when available to UK patients.
Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients
Donor privilege cards given to the families of all the donors from across Karnataka as a token of appreciation
Company creates Younger T Cells for fighting cancer using its NR2F6 technology
Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy
Sandu Kumarvin is an Ayurvedic digestive and immunity booster for children and also offers several other benefits.
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
Subscribe To Our Newsletter & Stay Updated
